Literature DB >> 27226251

The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo.

Sang W Hyun1, Anguo Liu1, Zhenguo Liu2, Alan S Cross3, Avelino C Verceles4, Sadagopan Magesh5, Yadagiri Kommagalla5, Chandrababunaidu Kona6, Hiromune Ando6, Irina G Luzina1, Sergei P Atamas7, Kurt H Piepenbrink8, Eric J Sundberg9, Wei Guang10, Hideharu Ishida5, Erik P Lillehoj10, Simeon E Goldblum11.   

Abstract

Neuraminidase-1 (NEU1) is the predominant sialidase expressed in human airway epithelia and lung microvascular endothelia where it mediates multiple biological processes. We tested whether the NEU1-selective sialidase inhibitor, C9-butyl-amide-2-deoxy-2,3-dehydro-N-acetylneuraminic acid (C9-BA-DANA), inhibits one or more established NEU1-mediated bioactivities in human lung cells. We established the IC50 values of C9-BA-DANA for total sialidase activity in human airway epithelia, lung microvascular endothelia and lung fibroblasts to be 3.74 µM, 13.0 µM and 4.82 µM, respectively. In human airway epithelia, C9-BA-DANA dose-dependently inhibited flagellin-induced, NEU1-mediated mucin-1 ectodomain desialylation, adhesiveness for Pseudomonas aeruginosa and shedding. In lung microvascular endothelia, C9-BA-DANA reversed NEU1-driven restraint of cell migration into a wound and disruption of capillary-like tube formation. NEU1 and its chaperone/transport protein, protective protein/cathepsin A (PPCA), were differentially expressed in these same cells. Normalized NEU1 protein expression correlated with total sialidase activity whereas PPCA expression did not. In contrast to eukaryotic sialidases, C9-BA-DANA exerted far less inhibitory activity for three selected bacterial neuraminidases (IC50 > 800 µM). Structural modeling of the four human sialidases and three bacterial neuraminidases revealed a loop between the seventh and eighth strands of the β-propeller fold, that in NEU1, was substantially shorter than that seen in the six other enzymes. Predicted steric hindrance between this loop and C9-BA-DANA could explain its selectivity for NEU1. Finally, pretreatment of mice with C9-BA-DANA completely protected against flagellin-induced increases in lung sialidase activity. Our combined data indicate that C9-BA-DANA inhibits endogenous and ectopically expressed sialidase activity and established NEU1-mediated bioactivities in human airway epithelia, lung microvascular endothelia, and fibroblasts in vitro and murine lungs in vivo.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  NEU1; PPCA; lung; neuraminidase; sialidase

Mesh:

Substances:

Year:  2016        PMID: 27226251      PMCID: PMC5884327          DOI: 10.1093/glycob/cww060

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  71 in total

Review 1.  The sialome--far more than the sum of its parts.

Authors:  Miriam Cohen; Ajit Varki
Journal:  OMICS       Date:  2010-08

2.  Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.

Authors:  Keiko Hata; Koichi Koseki; Kazunori Yamaguchi; Setsuko Moriya; Yasuo Suzuki; Sangchai Yingsakmongkon; Go Hirai; Mikiko Sodeoka; Mark von Itzstein; Taeko Miyagi
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

3.  NEU1 Sialidase Regulates Membrane-tethered Mucin (MUC1) Ectodomain Adhesiveness for Pseudomonas aeruginosa and Decoy Receptor Release.

Authors:  Erik P Lillehoj; Sang Won Hyun; Anguo Liu; Wei Guang; Avelino C Verceles; Irina G Luzina; Sergei P Atamas; K Chul Kim; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2015-05-11       Impact factor: 5.157

Review 4.  Features and applications of bacterial sialidases.

Authors:  Seonghun Kim; Doo-Byoung Oh; Hyun Ah Kang; Ohsuk Kwon
Journal:  Appl Microbiol Biotechnol       Date:  2011-05-05       Impact factor: 4.813

5.  G-protein coupled receptor agonists mediate Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of TOLL-like receptors and cellular signaling.

Authors:  Samar Abdulkhalek; Merry Guo; Schammim Ray Amith; Preethi Jayanth; Myron R Szewczuk
Journal:  Cell Signal       Date:  2012-07-01       Impact factor: 4.315

6.  [2-Deoxy-2,3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuraminic acids].

Authors:  P Meindl; H Tuppy
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1969-09

7.  Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: selective inhibitors of lysosomal sialidase (NEU1).

Authors:  Sadagopan Magesh; Setsuko Moriya; Tohru Suzuki; Taeko Miyagi; Hideharu Ishida; Makoto Kiso
Journal:  Bioorg Med Chem Lett       Date:  2007-11-28       Impact factor: 2.823

8.  Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling.

Authors:  Schammim Ray Amith; Preethi Jayanth; Susan Franchuk; Trisha Finlay; Volkan Seyrantepe; Rudi Beyaert; Alexey V Pshezhetsky; Myron R Szewczuk
Journal:  Cell Signal       Date:  2009-09-29       Impact factor: 4.315

9.  The Phyre2 web portal for protein modeling, prediction and analysis.

Authors:  Lawrence A Kelley; Stefans Mezulis; Christopher M Yates; Mark N Wass; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2015-05-07       Impact factor: 13.491

10.  Structural basis for substrate specificity of mammalian neuraminidases.

Authors:  Victoria Smutova; Amgad Albohy; Xuefang Pan; Elena Korchagina; Taeko Miyagi; Nicolai Bovin; Christopher W Cairo; Alexey V Pshezhetsky
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

View more
  13 in total

1.  Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against Pseudomonas aeruginosa lung infection.

Authors:  Erik P Lillehoj; Wei Guang; Sang W Hyun; Anguo Liu; Nicolas Hegerle; Raphael Simon; Alan S Cross; Hideharu Ishida; Irina G Luzina; Sergei P Atamas; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2018-11-14       Impact factor: 5.157

2.  Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.

Authors:  Irina G Luzina; Erik P Lillehoj; Virginia Lockatell; Sang W Hyun; Katerina N Lugkey; Akihiro Imamura; Hideharu Ishida; Christopher W Cairo; Sergei P Atamas; Simeon E Goldblum
Journal:  J Pharmacol Exp Ther       Date:  2020-11-02       Impact factor: 4.030

Review 3.  Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov.

Authors:  Victor Glanz; Evgeny E Bezsonov; Vladislav Soldatov; Alexander N Orekhov
Journal:  Biomedicines       Date:  2022-05-19

4.  Antibody against Microbial Neuraminidases Recognizes Human Sialidase 3 (NEU3): the Neuraminidase/Sialidase Superfamily Revisited.

Authors:  Chiguang Feng; Jihong Li; Greg Snyder; Wei Huang; Simeon E Goldblum; Wilbur H Chen; Lai-Xi Wang; Bruce A McClane; Alan S Cross
Journal:  MBio       Date:  2017-06-27       Impact factor: 7.867

Review 5.  Sialidases From Clostridium perfringens and Their Inhibitors.

Authors:  Yan-Hua Wang
Journal:  Front Cell Infect Microbiol       Date:  2020-01-10       Impact factor: 5.293

6.  Identification and Evaluation of New Potential Inhibitors of Human Neuraminidase 1 Extracted from Olyra latifolia L.: A Preliminary Study.

Authors:  Camille Albrecht; Zachée Louis Evariste Akissi; Philomène Akoua Yao-Kouassi; Abdulmagid Alabdul Magid; Pascal Maurice; Laurent Duca; Laurence Voutquenne-Nazabadioko; Amar Bennasroune
Journal:  Biomedicines       Date:  2021-04-11

Review 7.  The Elastin Receptor Complex: An Emerging Therapeutic Target Against Age-Related Vascular Diseases.

Authors:  Dignê Tembely; Aubéri Henry; Laetitia Vanalderwiert; Kevin Toussaint; Amar Bennasroune; Sébastien Blaise; Hervé Sartelet; Stéphane Jaisson; Céline Galés; Laurent Martiny; Laurent Duca; Béatrice Romier-Crouzet; Pascal Maurice
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-11       Impact factor: 5.555

8.  Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond.

Authors:  Erik P Lillehoj; Irina G Luzina; Sergei P Atamas
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

Review 9.  Inhibition of sialidase activity as a therapeutic approach.

Authors:  Victor Yu Glanz; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  Drug Des Devel Ther       Date:  2018-10-10       Impact factor: 4.162

10.  Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages.

Authors:  Maren Heimerl; Irina Sieve; Melanie Ricke-Hoch; Sergej Erschow; Karin Battmer; Michaela Scherr; Denise Hilfiker-Kleiner
Journal:  Basic Res Cardiol       Date:  2020-09-25       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.